

Joana Rocha-Pereira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1580689/publications.pdf>

Version: 2024-02-01

43
papers

2,297
citations

393982

19
h-index

276539

41
g-index

51
all docs

51
docs citations

51
times ranked

4461
citing authors

#	ARTICLE	IF	CITATIONS
1	Restriction of Viral Replication, Rather than T Cell Immunopathology, Drives Lethality in Murine Norovirus CR6-Infected STAT1-Deficient Mice. <i>Journal of Virology</i> , 2022, 96, jvi0206521.	1.5	1
2	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. <i>Antiviral Research</i> , 2022, 202, 105311.	1.9	8
3	Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Identification of active compounds. <i>Antiviral Chemistry and Chemotherapy</i> , 2021, 29, 204020662110268.	0.3	3
4	Screening and in vitro antiviral assessment of small molecules against fluorescent protein-expressing Bunyamwera virus in a cell-based assay using high-content imaging. <i>Antiviral Chemistry and Chemotherapy</i> , 2021, 29, 204020662110334.	0.3	3
5	Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Early mechanistic studies. <i>Antiviral Chemistry and Chemotherapy</i> , 2021, 29, 204020662110251.	0.3	1
6	Infection of zebrafish larvae with human norovirus and evaluation of the in vivo efficacy of small-molecule inhibitors. <i>Nature Protocols</i> , 2021, 16, 1830-1849.	5.5	20
7	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. <i>EBioMedicine</i> , 2021, 66, 103288.	2.7	21
8	Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections. <i>Microorganisms</i> , 2021, 9, 1599.	1.6	12
9	Structure-Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections. <i>Microorganisms</i> , 2021, 9, 1795.	1.6	1
10	A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo. <i>Viruses</i> , 2021, 13, 1852.	1.5	7
11	Discovery of a Novel Class of Norovirus Inhibitors with High Barrier of Resistance. <i>Pharmaceuticals</i> , 2021, 14, 1006.	1.7	0
12	An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. <i>Science Translational Medicine</i> , 2021, 13, eabi7826.	5.8	41
13	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26955-26965.	3.3	240
14	Animal models for COVID-19. <i>Nature</i> , 2020, 586, 509-515.	13.7	705
15	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. <i>Nature Communications</i> , 2020, 11, 5838.	5.8	225
16	Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3189-3193.	1.3	5
17	Diketo acids inhibit the cap-snatching endonuclease of several Bunyavirales. <i>Antiviral Research</i> , 2020, 183, 104947.	1.9	22
18	Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. <i>Nature Communications</i> , 2020, 11, 4253.	5.8	43

#	ARTICLE	IF	CITATIONS
19	Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides. <i>European Journal of Medicinal Chemistry</i> , 2020, 195, 112198.	2.6	14
20	A robust human norovirus replication model in zebrafish larvae. <i>PLoS Pathogens</i> , 2019, 15, e1008009.	2.1	112
21	Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy. <i>Viruses</i> , 2019, 11, 173.	1.5	18
22	Structural and functional similarities in bunyaviruses: Perspectives for pan-bunya antivirals. <i>Reviews in Medical Virology</i> , 2019, 29, e2039.	3.9	21
23	A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase. <i>Scientific Reports</i> , 2019, 9, 18413.	1.6	8
24	Interferon lambda (IFN- λ) efficiently blocks norovirus transmission in a mouse model. <i>Antiviral Research</i> , 2018, 149, 7-15.	1.9	24
25	Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon- λ . <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 469-479.	0.5	11
26	A Single Nucleoside Viral Polymerase Inhibitor Against Norovirus, Rotavirus, and Sapovirus-Induced Diarrhea. <i>Journal of Infectious Diseases</i> , 2018, 218, 1753-1758.	1.9	23
27	Assessing the Efficacy of Small Molecule Inhibitors in a Mouse Model of Persistent Norovirus Infection. <i>Bio-protocol</i> , 2018, 8, e2831.	0.2	1
28	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 139-142.	1.0	27
29	Norovirus genetic diversity and evolution: implications for antiviral therapy. <i>Current Opinion in Virology</i> , 2016, 20, 92-98.	2.6	17
30	Post-exposure antiviral treatment of norovirus infections effectively protects against diarrhea and reduces virus shedding in the stool in a mortality mouse model. <i>Antiviral Research</i> , 2016, 132, 76-84.	1.9	14
31	Inhibition of human norovirus by a viral polymerase inhibitor in the B cell culture system and in the mouse model. <i>Antiviral Research</i> , 2016, 132, 46-49.	1.9	54
32	Treatment with a Nucleoside Polymerase Inhibitor Reduces Shedding of Murine Norovirus in Stool to Undetectable Levels without Emergence of Drug-Resistant Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1907-1911.	1.4	13
33	Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 190-197.	1.3	31
34	Molecular Chaperone Hsp90 Is a Therapeutic Target for Noroviruses. <i>Journal of Virology</i> , 2015, 89, 6352-6363.	1.5	51
35	ID: 146. <i>Cytokine</i> , 2015, 76, 94.	1.4	1
36	The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic Anti-Norovirus Activity and Clears Cells from the Norovirus Replicon. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4675-4681.	1.4	45

#	ARTICLE	IF	CITATIONS
37	Norovirus: Targets and tools in antiviral drug discovery. <i>Biochemical Pharmacology</i> , 2014, 91, 1-11.	2.0	49
38	The Viral Polymerase Inhibitor 2- <i>C</i> -Methylcytidine Inhibits Norwalk Virus Replication and Protects against Norovirus-Induced Diarrhea and Mortality in a Mouse Model. <i>Journal of Virology</i> , 2013, 87, 11798-11805.	1.5	85
39	Favipiravir (T-705) inhibits in vitro norovirus replication. <i>Biochemical and Biophysical Research Communications</i> , 2012, 424, 777-780.	1.0	122
40	Inhibition of norovirus replication by the nucleoside analogue 2- <i>C</i> -methylcytidine. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 796-800.	1.0	59
41	Outbreak of acute gastroenteritis caused by adenovirus type 41 in a kindergarten. <i>Epidemiology and Infection</i> , 2011, 139, 1672-1675.	1.0	13
42	(E)-2-Styrylchromones as potential anti-norovirus agents. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 4195-4201.	1.4	48
43	Targeting Norovirus: Strategies for the Discovery of New Antiviral Drugs. , 0, , .		4